Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
MAGE-A4 TCR-T cell therapy
Afamitresgene autoleucel (Afami-cel)
Tecelra · MAGE-A4 TCR-T therapy
MAGE-A4-directed TCR T-cell therapy; renal risk is CRS-associated and hemodynamic, not a direct nephrotoxin.
ModerateMAGE-A4 TCR-engineered T-cell therapy · approved 2024
Unresectable or metastatic synovial sarcoma in HLA-A*02-eligible adults who have received prior chemotherapy and whose tumor expresses MAGE-A4 (accelerated approval)
Signature kidney injury
Prerenal / Hemodynamic AKI
Drug-specific renal injury rates for afami-cel are not well defined; the SPEARHEAD-1 trial reported cytokine release syndrome (CRS) in most treated patients, predominantly low grade, as the dominant systemic toxicity. Acute kidney injury is best understood as a downstream, CRS-associated hemodynamic event rather than a measured signature toxicity. By analogy to CAR-T cellular therapy, AKI incidence in the broader engineered-T-cell setting spans roughly 5 to 33 percent depending on population and CRS severity. A precise afami-cel-specific incidence cannot be stated from current literature.
Source: 38554725
Mechanism of kidney injury
The principal renal mechanism is hemodynamic (prerenal). CRS-driven systemic inflammation produces fever, vasodilation, capillary leak, and hypotension that reduce renal perfusion; superimposed tumor lysis can add an intratubular/metabolic insult. Afami-cel is not a direct tubular nephrotoxin; rather, the kidney is an innocent bystander to the inflammatory and hemodynamic storm, analogous to CRS-associated AKI described with CAR-T therapy.
Clinical presentation
Presentation typically tracks the CRS course: fever and hypotension with a rise in creatinine and reduced urine output. Sediment is usually bland, consistent with prerenal physiology or early ischemic tubular injury; electrolyte derangements may accompany concurrent tumor lysis.
Anticancer mechanism
Afamitresgene autoleucel is an autologous T-cell therapy engineered to express an affinity-enhanced T-cell receptor (TCR) recognizing a MAGE-A4 peptide presented on HLA-A*02. The modified T cells recognize and kill MAGE-A4-expressing tumor cells in HLA-A*02-positive patients. It received accelerated FDA approval in August 2024 for advanced synovial sarcoma, becoming the first engineered TCR T-cell therapy approved for a solid tumor.
Management
Management mirrors CRS-associated AKI care: restore renal perfusion with fluid resuscitation and vasopressors as needed, treat the underlying CRS (e.g., tocilizumab, corticosteroids per protocol), and manage tumor lysis with hydration and urate-lowering agents. Most cases are hemodynamic and improve as CRS resolves; renal replacement therapy is reserved for refractory or severe AKI.Lesion-level management framework
Risk factors
- Higher-grade cytokine release syndrome
- Pre-existing chronic kidney disease or reduced baseline GFR
- Volume depletion and hypotension
- High tumor burden predisposing to tumor lysis
- Concomitant nephrotoxins
Prevention
- Pre-infusion optimization of volume status and renal function
- Early recognition and grading of CRS
- Prompt CRS-directed therapy (tocilizumab, supportive care) to limit hemodynamic insult
- Tumor lysis prophylaxis (hydration, urate-lowering therapy) in high-burden disease
- Avoid overlapping nephrotoxins and contrast where feasible
Clinical depth
Renal dose adjustment
Not applicable in the conventional sense - this is a one-time autologous cell product, not a renally cleared small molecule, so there are no CrCl-based dose thresholds. No renal dose adjustment is established; lymphodepleting chemotherapy given before infusion may itself require attention to renal function.
Dialyzability & ESKD dosing
Not applicable. As a living-cell therapy, afami-cel is not dialyzable; dialysis is used only to support severe AKI, not to clear the product.
Differential diagnosis
In a treated patient with rising creatinine, separate CRS-driven prerenal/ischemic AKI from tumor lysis syndrome (hyperuricemia, hyperphosphatemia, hyperkalemia) and from lymphodepletion-related or concomitant nephrotoxin injury. The temporal link to fever and hypotension points to CRS-associated hemodynamic AKI.
Monitoring
- Serum creatinine and urine output during and after the CRS window
- Vital signs for hypotension/fever (CRS grading)
- Electrolytes, phosphate, uric acid, and LDH for tumor lysis
- Volume status
Key trials & series
- SPEARHEAD-1 (NCT04044768): international open-label phase 2 of afami-cel in advanced synovial sarcoma and myxoid round cell liposarcoma; supported accelerated approval. CRS was common but predominantly low grade, framing renal risk as CRS-associated and hemodynamic.
Clinical pearls
- Frame renal injury as CRS-associated and hemodynamic (prerenal), not as direct tubular nephrotoxicity from the cell product.
- AKI clusters with the CRS window in the first days to ~2 weeks; controlling CRS is the main renal-protective lever.
- Tumor lysis is a co-traveler in high-burden disease and adds an intratubular/metabolic insult.
- There are no CrCl dose thresholds - this is a one-time autologous TCR-T product, so renal management is supportive.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Evidence
3 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkAfamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.D'Angelo SP, Araujo DM, Abdul Razak AR, et al. · Lancet 2024 · PMID 38554725Pivotal SPEARHEAD-1 trial supporting approval; documents CRS as the dominant systemic toxicity, the basis for CRS-associated hemodynamic renal risk.PMIDAcute kidney injury following CAR-T cell therapy: a nephrologist's perspective.Kanbay M, Mizrak B, Alper EN, Copur S, Ortiz A. · Clin Kidney J 2024 · PMID 39781479Nephrology review of engineered-T-cell-associated AKI detailing CRS, tumor lysis, and hemodynamic mechanisms; applicable to TCR-T CRS-associated renal injury.PMIDAcute Kidney Injury Associated with Novel Anticancer Therapies: Immunotherapy.Karam S, Ali A, Fung W, Mehta P, Nair S, Anandh U. · Kidney360 2025 · PMID 39992727Class-level onconephrology review of immunotherapy-associated AKI, including CRS and inflammatory mechanisms relevant to engineered cellular therapies.
Guidelines & consensus· 12
General onco-nephrology references
Acute Disease Quality InitiativeThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.Cancer Institute NSWIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.Cancer Institute NSWAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.Cancer Institute NSWA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.